Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111206

Cover Image

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111206

Europe Glioblastoma Multiforme Treatment Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 275 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Web Access (Single User License) - Read Only
USD 3500
Web Access (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

The glioblastoma multiforme treatment market is projected to register a substantial CAGR of 8.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

Europe Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary), Treatment (Surgery, Radiotherapy, Medications), Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administratin (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the glioblastoma multiforme treatment market are:

Increasing prevalence of the disease

High incidence in emerging markets.

Market Players:

Some of the major players operating in the market are:

F. Hoffmann-La Roche AG

Amgen Inc.

Merck & Co., Inc.

Pfizer Inc.

Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare)

ZEISS International

Amneal Pharmaceuticals LLC

Elekta

Sun Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd.

Eckert & Ziegler

Accord Healthcare

Angiochem

ANI Pharmaceuticals, Inc.

Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.)

AstraZeneca

Cantex Pharmaceuticals, Inc.

CELON LABS

Diffusion Pharmaceuticals Inc.

EnGeneIC

ERC.SA.

Genenta science

Jazz Pharmaceuticals, Inc.

Loxo Oncology (A Subsidiary of Eli Lilly)

Novartis AG

VBL THERAPEUTICS

Viatris Inc.

Zydus Pharmaceuticals, Inc.,

TABLE OF CONTENTS

1 INTRODUCTION 53

  • 1.1 OBJECTIVES OF THE STUDY 53
  • 1.2 MARKET DEFINITION 53
  • 1.3 OVERVIEW OF EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET 53
  • 1.4 LIMITATIONS 55
  • 1.5 MARKETS COVERED 56

2 MARKET SEGMENTATION 59

  • 2.1 MARKETS COVERED 59
  • 2.2 GEOGRAPHICAL SCOPE 60
  • 2.3 YEARS CONSIDERED FOR THE STUDY 61
  • 2.4 CURRENCY AND PRICING 61
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
  • 2.6 MULTIVARIATE MODELLING 65
  • 2.7 TYPE LIFELINE CURVE 65
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
  • 2.9 DBMR MARKET POSITION GRID 67
  • 2.10 MARKET END USER COVERAGE GRID 68
  • 2.11 VENDOR SHARE ANALYSIS 69
  • 2.12 SECONDARY SOURCES 70
  • 2.13 ASSUMPTIONS 70

3 EXECUTIVE SUMMARY 71

4 PREMIUM INSIGHTS 75

  • 4.1 PESTEL 76
  • 4.2 PORTER'S FIVE FORCES MODEL 77

5 EPIDEMIOLOGY 78

6 PIPELINE ANALYSIS 80

7 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: REGULATORY SCENARIO 82

8 MARKET OVERVIEW 84

  • 8.1 DRIVERS 86
    • 8.1.1 GROWING PREVALENCE OF GLIOBLASTOMA MULTIFORME 86
    • 8.1.2 INCREASING RESEARCH AND DEVELOPMENT (R&D) 86
    • 8.1.3 PRESENCE OF A STRONG PIPELINE 87
    • 8.1.4 GROWING GERIATRIC POPULATION 88
  • 8.2 RESTRAINTS 89
    • 8.2.1 HIGH COST OF GLIOBLASTOMA MULTIFORME TREATMENT 89
    • 8.2.2 ADVERSE SIDE-EFFECTS OF GLIOBLASTOMA MULTIFORME TREATMENT 90
  • 8.3 OPPORTUNITIES 90
    • 8.3.1 INCREASING DRUG APPROVALS 90
    • 8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 91
    • 8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT 91
  • 8.4 CHALLENGES 92
    • 8.4.1 LACK OF NEW TREATMENT 92
    • 8.4.2 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS 92
    • 8.4.3 LACK OF EARLY DETECTION 93

9 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE 94

  • 9.1 OVERVIEW 95
  • 9.2 PRIMARY (DE NOVO) 98
  • 9.3 SECONDARY 98

10 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT 100

  • 10.1 OVERVIEW 101
  • 10.2 SURGERY 104
  • 10.3 RADIOTHERAPY 104
    • 10.3.1 BRACHYTHERAPY 105
    • 10.3.2 FRACTIONATED STEREOTACTIC RT (FSRT) 105
    • 10.3.3 CONFORMAL OR INTENSITY-MODULATED RT 105
    • 10.3.4 RADIOSURGERY 106
  • 10.4 MEDICATIONS 106
    • 10.4.1 TEMOZOLOMIDE 107
      • 10.4.1.1 ORAL 107
      • 10.4.1.1 INTRAVENOUS 107
    • 10.4.2 NITROSOUREAS DRUGS 107
      • 10.4.2.1 CARMUSTINE 108
        • 10.4.2.1.1 PARENTERAL 108
        • 10.4.2.1.2 IMPLANTABLE WAFERS 108
      • 10.4.2.2 LOMUSTINE 108
      • 10.4.2.3 NIMUSTINE 109
      • 10.4.2.4 FOTEMUSTINE 109
    • 10.4.3 TARGETED THERAPY 109
      • 10.4.3.1 BEVACIZUMAB 109
      • 10.4.3.2 OTHERS 109
    • 10.4.4 ANTI-EPILEPTICS 109
      • 10.4.4.1 LEVETIRACETAM 110
      • 10.4.4.2 PHENYTOIN 110
      • 10.4.4.3 CARBAMAZEPINE 110
    • 10.4.5 CORTICOSTEROIDS 110
      • 10.4.5.1 METHYLPREDNISOLONE 111
      • 10.4.5.2 PREDNISONE 111
      • 10.4.5.3 OTHERS 111

11 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE 112

  • 11.1 OVERVIEW 113
  • 11.2 ADULT 116
    • 11.2.1 MALE 116
    • 11.2.2 FEMALE 117
  • 11.3 GERIATRIC 117
    • 11.3.1 MALE 118
    • 11.3.2 FEMALE 118
  • 11.4 CHILD 118

12 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE 120

  • 12.1 OVERVIEW 121
  • 12.2 GENERICS 124
  • 12.3 BRANDED 124

13 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 126

  • 13.1 OVERVIEW 127
  • 13.2 PARENTERAL 130
  • 13.3 ORAL 130
    • 13.3.1 CAPSULES 131
    • 13.3.2 TABLETS 131
    • 13.3.3 POWDERS 131
  • 13.4 OTHERS 131

14 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER 133

  • 14.1 OVERVIEW 134
  • 14.2 HOSPITAL 137
  • 14.3 CLINICS 137
  • 14.4 HOME HEALTHCARE 138
  • 14.5 OTHERS 139

15 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL 140

  • 15.1 OVERVIEW 141
  • 15.2 HOSPITAL PHARMACY 144
  • 15.3 RETAIL PHARMACY 144
  • 15.4 ONLINE PHARMACY 145
  • 15.5 OTHERS 145

16 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION 147

  • 16.1 EUROPE 148
    • 16.1.1 GERMANY 158
    • 16.1.2 FRANCE 162
    • 16.1.3 U.K. 166
    • 16.1.4 ITALY 170
    • 16.1.5 SPAIN 174
    • 16.1.6 RUSSIA 178
    • 16.1.7 SWITZERLAND 182
    • 16.1.8 NETHERLANDS 186
    • 16.1.9 HUNGARY 190
    • 16.1.10 POLAND 194
    • 16.1.11 AUSTRIA 198
    • 16.1.12 IRELAND 202
    • 16.1.13 NORWAY 206
    • 16.1.14 LITHUANIA 210
    • 16.1.15 TURKEY 214
    • 16.1.16 REST OF EUROPE 218

17 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE 219

  • 17.1 COMPANY SHARE ANALYSIS: EUROPE 219

18 SWOT ANALYSIS 220

19 COMPANY PROFILE 221

  • 19.1 F.HOFFMAN-LA ROCHE 221
    • 19.1.1 COMPANY SNAPSHOT 221
    • 19.1.2 REVENUE ANALYSIS 221
    • 19.1.3 COMPANY SHARE ANALYSIS 222
    • 19.1.4 PRODUCT PORTFOLIO 222
    • 19.1.5 RECENT DEVELOPMENT 222
  • 19.2 AMGEN INC. 223
    • 19.2.1 COMPANY SNAPSHOT 223
    • 19.2.2 REVENUE ANALYSIS 223
    • 19.2.3 COMPANY SHARE ANALYSIS 224
    • 19.2.4 PRODUCT PORTFOLIO 224
    • 19.2.5 RECENT DEVELOPMENTS 224
      • 19.2.5.1 PRODUCT APPROVAL 224
  • 19.3 MERCK & CO., INC 225
    • 19.3.1 COMPANY SNAPSHOT 225
    • 19.3.2 REVENUE ANALYSIS 225
    • 19.3.3 COMPANY SHARE ANALYSIS 226
    • 19.3.4 PRODUCT PORTFOLIO 226
    • 19.3.5 RECENT DEVELOPMENTS 226
      • 19.3.5.1 STRATETIC COLLABORATION 226
      • 19.3.5.2 EVENTS 227
  • 19.4 PFIZER INC. 228
    • 19.4.1 COMPANY SNAPSHOT 228
    • 19.4.2 REVENUE ANALYSIS 228
    • 19.4.3 COMPANY SHARE ANALYSIS 229
    • 19.4.4 PRODUCT PORTFOLIO 229
    • 19.4.5 RECENT DEVELOPMENT 229
      • 19.4.5.1 MERGER 229
  • 19.5 VARIAN MEDICAL SYSTEMS, INC. (A SUBSIDIARY OF SIEMENS HEALTHCARE) 230
    • 19.5.1 COMPANY SNAPSHOT 230
    • 19.5.2 REVENUE ANALYSIS 230
    • 19.5.3 COMPANY SHARE ANALYSIS 231
    • 19.5.4 PRODUCT PORTFOLIO 231
    • 19.5.5 RECENT DEVELOPMENT 231
      • 19.5.5.1 PARTNERSHIP 231
      • 19.5.5.2 ACQUISITION 232 
  • 19.6 ZEISS INTERNATIONAL 233
    • 19.6.1 COMPANY SNAPSHOT 233
    • 19.6.2 REVENUE ANALYSIS 233
    • 19.6.3 PRODUCT PORTFOLIO 234
    • 19.6.4 RECENT DEVELOPMENTS 234
      • 19.6.4.1 PRODUCT EXPANSION 234
  • 19.7 AMNEAL PHARMACEUTICALS LLC 235
    • 19.7.1 COMPANY SNAPSHOT 235
    • 19.7.2 REVENUE ANALYSIS 235
    • 19.7.3 PRODUCT PORTFOLIO 236
    • 19.7.4 RECENT DEVELOPMENTS 236
      • 19.7.4.1 EVENT 236
      • 19.7.4.2 LAUNCH 236
      • 19.7.4.3 ACQUISITION 237
  • 19.8 ELEKTA 238
    • 19.8.1 COMPANY SNAPSHOT 238
    • 19.8.2 REVENUE ANALYSIS 238
    • 19.8.3 PRODUCT PORTFOLIO 239
    • 19.8.4 RECENT DEVELOPMENTS 239
      • 19.8.4.1 PARTNERSHIP 239
  • 19.9 SUN PHARMACEUTICAL INDUSTRIES LTD 240
    • 19.9.1 COMPANY SNAPSHOT 240
    • 19.9.2 REVENUE ANALYSIS 240
    • 19.9.3 PRODUCT PORTFOLIO 241
    • 19.9.4 RECENT DEVELOPMENT 241
      • 19.9.4.1 AGREEMENT 241
  • 19.10 TEVA PHARMACEUTICAL INDUSTRIES LTD 242
    • 19.10.1 COMPANY SNAPSHOT 242
    • 19.10.2 REVENUE ANALYSIS 242
    • 19.10.3 PRODUCT PORTFOLIO 243
    • 19.10.4 RECENT DEVELOPMENT 243
  • 19.11 ECKERT & ZIEGLER 244
    • 19.11.1 COMPANY SNAPSHOT 244
    • 19.11.2 REVENUE ANALYSIS 244
    • 19.11.3 PRODUCT PORTFOLIO 245
    • 19.11.4 RECENT DEVELOPMENT 245
  • 19.12 ACCORD HEALTHCARE 246
    • 19.12.1 COMPANY SNAPSHOT 246
    • 19.12.2 PRODUCT PORTFOLIO 246
    • 19.12.3 RECENT DEVELOPMENT 246
  • 19.13 ANGIOCHEM 247
    • 19.13.1 COMPANY SNAPSHOT 247
    • 19.13.2 PRODUCT PORTFOLIO 247
    • 19.13.3 RECENT DEVELOPMENT 247
      • 19.13.3.1 AGREMEENT 247
  • 19.14 ANI PHARMACEUTICALS, INC. 248
    • 19.14.1 COMPANY SNAPSHOT 248
    • 19.14.2 REVENUE ANALYSIS 248
    • 19.14.3 PRODUCT PORTFOLIO 249
    • 19.14.4 RECENT DEVELOPMENTS 249
      • 19.14.4.1 ACQUISITION 249
  • 19.15 ARBOR PHARMACEUTICALS, LLC. A SUBSIDIARY OF AZURITY PHARMACEUTICALS, INC. 250
    • 19.15.1 COMPANY SNAPSHOT 250
    • 19.15.2 PRODUCT PORTFOLIO 250
    • 19.15.3 RECENT DEVELOPMENT 250
      • 19.15.3.1 ACQUISITION 250
      • 19.15.3.2 PRODUCT APPROVAL 251
  • 19.16 ASTRAZENECA 252
    • 19.16.1 COMPANY SNAPSHOT 252
    • 19.16.2 REVENUE ANALYSIS 252
    • 19.16.3 PRODUCT PORTFOLIO 253
    • 19.16.4 RECENT DEVELOPMENT 253
      • 19.16.4.1 AGREEMENT 253
  • 19.17 CANTEX PHARMACEUTICALS, INC. 254
    • 19.17.1 COMPANY SNAPSHOT 254
    • 19.17.2 PRODUCT PORTFOLIO 254
    • 19.17.3 RECENT DEVELOPMENT 254
  • 19.18 CELON LABS 255
    • 19.18.1 COMPANY SNAPSHOT 255
    • 19.18.2 PRODUCT PORTFOLIO 255
    • 19.18.3 RECENT DEVELOPMENT 255
  • 19.19 DIFFUSION PHARMACEUTICAL 256
    • 19.19.1 COMPANY SNAPSHOT 256
    • 19.19.2 SERVICES PORTFOLIO 256
    • 19.19.3 RECENT DEVELOPMENT 256
  • 19.20 ERC.SA 257
    • 19.20.1 COMPANY SNAPSHOT 257
    • 19.20.2 PRODUCT PORTFOLIO 257
    • 19.20.3 RECENT DEVELOPMENT 257
      • 19.20.3.1 PIPELINE UPDATE 257
  • 9.21 ENGENEIC 258
    • 19.21.1 COMPANY SNAPSHOT 258
    • 19.21.2 PRODUCT PORTFOLIO 258
    • 19.21.3 RECENT DEVELOPMENTS 258
    • 19.2.1 AWARDS 259
  • 19.22 GENENTA SCIENCE 260
    • 19.22.1 COMPANY SNAPSHOT 260
    • 19.22.2 PRODUCT PORTFOLIO 260
    • 19.22.3 RECENT DEVELOPMENT 260
      • 19.22.3.1 EVENT 260
  • 19.23 JAZZ PHARMACEUTICALS, INC. 261
    • 19.23.1 COMPANY SNAPSHOT 261
    • 19.23.2 REVENUE ANALYSIS 261
    • 19.23.3 PRODUCT PORTFOLIO 262
    • 19.23.4 RECENT DEVELOPMENT 262
      • 19.23.4.1 ACQUISITION 262
  • 19.24 LOXO ONCOLOGY (A SUBSIDIARY OF ELI LILLY) 263
    • 19.24.1 COMPANY SNAPSHOT 263
    • 19.24.2 PRODUCT PORTFOLIO 263
    • 19.24.3 RECENT DEVELOPMENT 263
  • 19.25 NOVARTIS AG 264
    • 19.25.1 COMPANY SNAPSHOT 264
    • 19.25.2 REVENUE ANALYSIS 264
    • 19.25.3 PRODUCT PORTFOLIO 265
    • 19.25.4 RECENT DEVELOPMENT 265
  • 19.26 VBL THERAPEUTICS 266
    • 19.26.1 COMPANY SNAPSHOT 266
    • 19.26.2 PRODUCT PORTFOLIO 266
    • 19.26.3 RECENT DEVELOPMENT 266
      • 19.26.3.1 EVENT 266
      • 19.26.3.2 AWARD 267
  • 19.27 VIATRIS INC 268
    • 19.27.1 COMPANY SNAPSHOT 268
    • 19.27.2 REVENUE ANALYSIS 268
    • 19.27.3 PRODUCT PORTFOLIO 269
    • 19.27.4 RECENT DEVELOPMENT 269
      • 19.27.4.1 AGREEMENT 269

  • 19.28 ZYDUS PHARMACEUTICALS, INC. 270
    • 19.28.1 COMPANY SNAPSHOT 270
    • 19.28.2 PRODUCT PORTFOLIO 270
    • 19.28.3 RECENT DEVELOPMENTS 270

20 QUESTIONNAIRE 271

21 RELATED REPORTS 275

LIST OF TABLES

  • TABLE 1 PIPELINE ANALYSIS FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET 58
  • TABLE 2 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 75
  • TABLE 3 EUROPE PRIMARY (DE NOVO) IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 76
  • TABLE 4 EUROPE SECONDARY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 77
  • TABLE 5 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 81
  • TABLE 6 EUROPE SURGERY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 82
  • TABLE 7 EUROPE RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 83
  • TABLE 8 EUROPE RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 83
  • TABLE 9 EUROPE MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 84
  • TABLE 10 EUROPE MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 85
  • TABLE 11 EUROPE TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 85
  • TABLE 12 EUROPE NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 86
  • TABLE 13 EUROPE CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 86
  • TABLE 14 EUROPE TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 87
  • TABLE 15 EUROPE ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 88
  • TABLE 16 EUROPE CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 88
  • TABLE 17 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 93
  • TABLE 18 EUROPE ADULTS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 94
  • TABLE 19 EUROPE ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 94
  • TABLE 20 EUROPE GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 95
  • TABLE 21 EUROPE GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 96
  • TABLE 22 EUROPE CHILD IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 97
  • TABLE 23 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 101
  • TABLE 24 EUROPE GENERICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 102
  • TABLE 25 EUROPE BRANDED IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 103
  • TABLE 26 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 107
  • TABLE 27 EUROPE PARENTERAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 28 EUROPE ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 109
  • TABLE 29 EUROPE ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 109
  • TABLE 30 EUROPE OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 110
  • TABLE 31 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 114
  • TABLE 32 EUROPE HOSPITAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 115
  • TABLE 33 EUROPE CLINICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 116
  • TABLE 34 EUROPE HOME HEALTHCARE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 116
  • TABLE 35 EUROPE OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 117
  • TABLE 36 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 121
  • TABLE 37 EUROPE HOSPITAL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 122
  • TABLE 38 EUROPE RETAIL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 123
  • TABLE 39 EUROPE ONLINE PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 123
  • TABLE 40 EUROPE OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 124
  • TABLE 41 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 131
  • TABLE 42 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 43 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 44 EUROPE RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 45 EUROPE MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 46 EUROPE TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 47 EUROPE NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 48 EUROPE CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 133
  • TABLE 49 EUROPE TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 133
  • TABLE 50 EUROPE ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 133
  • TABLE 51 EUROPE CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 133
  • TABLE 52 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 133
  • TABLE 53 EUROPE ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 54 EUROPE GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 55 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 56 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 134
  • TABLE 57 EUROPE ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 134
  • TABLE 58 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 135
  • TABLE 59 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 135
  • TABLE 60 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 61 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 62 GERMANY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 63 GERMANY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 64 GERMANY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 137
  • TABLE 65 GERMANY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 137
  • TABLE 66 GERMANY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 137
  • TABLE 67 GERMANY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 137
  • TABLE 68 GERMANY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 137
  • TABLE 69 GERMANY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 138
  • TABLE 70 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 71 GERMANY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 72 GERMANY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 73 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 74 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 139
  • TABLE 75 GERMANY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 139
  • TABLE 76 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 139
  • TABLE 77 GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 139
  • TABLE 78 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 79 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 80 FRANCE RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 81 FRANCE MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 140
  • TABLE 82 FRANCE TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 141
  • TABLE 83 FRANCE NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 141
  • TABLE 84 FRANCE CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 141
  • TABLE 85 FRANCE TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 141
  • TABLE 86 FRANCE ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 141
  • TABLE 87 FRANCE CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 142
  • TABLE 88 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 89 FRANCE ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 90 FRANCE GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 91 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 92 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 143
  • TABLE 93 FRANCE ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 143
  • TABLE 94 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 143
  • TABLE 95 FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 143
  • TABLE 96 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 97 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 144
  • TABLE 98 U.K. RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 144
  • TABLE 99 U.K. MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 144
  • TABLE 100 U.K. TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 145
  • TABLE 101 U.K. NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 145
  • TABLE 102 U.K. CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 145
  • TABLE 103 U.K. TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 145
  • TABLE 104 U.K. ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 145
  • TABLE 105 U.K. CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 146
  • TABLE 106 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 107 U.K. ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 108 U.K. GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 109 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 110 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 147
  • TABLE 111 U.K. ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 147
  • TABLE 112 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 147
  • TABLE 113 U.K. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 147
  • TABLE 114 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 115 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 148
  • TABLE 116 ITALY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 148
  • TABLE 117 ITALY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 148
  • TABLE 118 ITALY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 149
  • TABLE 119 ITALY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 149
  • TABLE 120 ITALY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 149
  • TABLE 121 ITALY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 149
  • TABLE 122 ITALY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 149
  • TABLE 123 ITALY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 150
  • TABLE 124 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 125 ITALY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 126 ITALY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 127 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 128 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 151
  • TABLE 129 ITALY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 151
  • TABLE 130 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 151
  • TABLE 131 ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 151
  • TABLE 132 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 133 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 152
  • TABLE 134 SPAIN RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 152
  • TABLE 135 SPAIN MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 152
  • TABLE 136 SPAIN TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 153
  • TABLE 137 SPAIN NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 153
  • TABLE 138 SPAIN CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 153
  • TABLE 139 SPAIN TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 153
  • TABLE 140 SPAIN ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 153
  • TABLE 141 SPAIN CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 154
  • TABLE 142 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 154
  • TABLE 143 SPAIN ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 154
  • TABLE 144 SPAIN GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 154
  • TABLE 145 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 154
  • TABLE 146 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 155
  • TABLE 147 SPAIN ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 155
  • TABLE 148 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 155
  • TABLE 149 SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 155
  • TABLE 150 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 151 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 156
  • TABLE 152 RUSSIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 156
  • TABLE 153 RUSSIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 156
  • TABLE 154 RUSSIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 157
  • TABLE 155 RUSSIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 157
  • TABLE 156 RUSSIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 157
  • TABLE 157 RUSSIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 157
  • TABLE 158 RUSSIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 157
  • TABLE 159 RUSSIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 158
  • TABLE 160 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 161 RUSSIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 162 RUSSIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 163 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 164 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 159
  • TABLE 165 RUSSIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 159
  • TABLE 166 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 159
  • TABLE 167 RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 159
  • TABLE 168 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 169 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 160
  • TABLE 170 SWITZERLAND RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 160
  • TABLE 171 SWITZERLAND MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 160
  • TABLE 172 SWITZERLAND TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 161
  • TABLE 173 SWITZERLAND NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 161
  • TABLE 174 SWITZERLAND CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 161
  • TABLE 175 SWITZERLAND TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 161
  • TABLE 176 SWITZERLAND ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 161
  • TABLE 177 SWITZERLAND CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 162
  • TABLE 178 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 179 SWITZERLAND ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 180 SWITZERLAND GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 181 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 182 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 163
  • TABLE 183 SWITZERLAND ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 163
  • TABLE 184 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 163
  • TABLE 185 SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 163
  • TABLE 186 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 187 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 164
  • TABLE 188 NETHERLANDS RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 164
  • TABLE 189 NETHERLANDS MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 164
  • TABLE 190 NETHERLANDS TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 165
  • TABLE 191 NETHERLANDS NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 165
  • TABLE 192 NETHERLANDS CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 165
  • TABLE 193 NETHERLANDS TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 165
  • TABLE 194 NETHERLANDS ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 165
  • TABLE 195 NETHERLANDS CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 166
  • TABLE 196 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 197 NETHERLANDS ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 198 NETHERLANDS GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 199 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 200 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 167
  • TABLE 201 NETHERLANDS ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 167
  • TABLE 202 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 167
  • TABLE 203 NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 167
  • TABLE 204 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 205 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 168
  • TABLE 206 HUNGARY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 168
  • TABLE 207 HUNGARY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 168
  • TABLE 208 HUNGARY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 169
  • TABLE 209 HUNGARY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 169
  • TABLE 210 HUNGARY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 169
  • TABLE 211 HUNGARY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 169
  • TABLE 212 HUNGARY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 169
  • TABLE 213 HUNGARY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 170
  • TABLE 214 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 215 HUNGARY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 216 HUNGARY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 217 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 218 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 171
  • TABLE 219 HUNGARY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 171
  • TABLE 220 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 171
  • TABLE 221 HUNGARY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 171
  • TABLE 222 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 172
  • TABLE 223 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 172
  • TABLE 224 POLAND RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 172
  • TABLE 225 POLAND MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 172
  • TABLE 226 POLAND TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 173
  • TABLE 227 POLAND NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 173
  • TABLE 228 POLAND CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 173
  • TABLE 229 POLAND TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 173
  • TABLE 230 POLAND ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 173
  • TABLE 231 POLAND CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 174
  • TABLE 232 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 233 POLAND ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 234 POLAND GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 235 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 236 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 175
  • TABLE 237 POLAND ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 175
  • TABLE 238 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 175
  • TABLE 239 POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 175
  • TABLE 240 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 241 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 176
  • TABLE 242 AUSTRIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 176
  • TABLE 243 AUSTRIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 176
  • TABLE 244 AUSTRIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 177
  • TABLE 245 AUSTRIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 177
  • TABLE 246 AUSTRIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 177
  • TABLE 247 AUSTRIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 177
  • TABLE 248 AUSTRIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 177
  • TABLE 249 AUSTRIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 178
  • TABLE 250 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 178
  • TABLE 251 AUSTRIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 178
  • TABLE 252 AUSTRIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 178
  • TABLE 253 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 178
  • TABLE 254 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 179
  • TABLE 255 AUSTRIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 179
  • TABLE 256 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 179
  • TABLE 257 AUSTRIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 179
  • TABLE 258 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 180
  • TABLE 259 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 180
  • TABLE 260 IRELAND RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 180
  • TABLE 261 IRELAND MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 180
  • TABLE 262 IRELAND TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 181
  • TABLE 263 IRELAND NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 181
  • TABLE 264 IRELAND CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 181
  • TABLE 265 IRELAND TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 181
  • TABLE 266 IRELAND ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 181
  • TABLE 267 IRELAND CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 182
  • TABLE 268 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 182
  • TABLE 269 IRELAND ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 182
  • TABLE 270 IRELAND GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 182
  • TABLE 271 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 182
  • TABLE 272 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 183
  • TABLE 273 IRELAND ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 183
  • TABLE 274 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 183
  • TABLE 275 IRELAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 183
  • TABLE 276 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 184
  • TABLE 277 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 184
  • TABLE 278 NORWAY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 184
  • TABLE 279 NORWAY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 184
  • TABLE 280 NORWAY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 281 NORWAY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 282 NORWAY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 283 NORWAY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 284 NORWAY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 185
  • TABLE 285 NORWAY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 186
  • TABLE 286 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 287 NORWAY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 288 NORWAY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 289 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 186
  • TABLE 290 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 187
  • TABLE 291 NORWAY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 187
  • TABLE 292 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 187
  • TABLE 293 NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 187
  • TABLE 294 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 188
  • TABLE 295 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 188
  • TABLE 296 LITHUANIA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 188
  • TABLE 297 LITHUANIA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 188
  • TABLE 298 LITHUANIA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 299 LITHUANIA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 300 LITHUANIA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 301 LITHUANIA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 302 LITHUANIA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 189
  • TABLE 303 LITHUANIA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 190
  • TABLE 304 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 305 LITHUANIA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 306 LITHUANIA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 307 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 190
  • TABLE 308 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 191
  • TABLE 309 LITHUANIA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 191
  • TABLE 310 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 191
  • TABLE 311 LITHUANIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 191
  • TABLE 312 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 192
  • TABLE 313 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 192
  • TABLE 314 TURKEY RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 192
  • TABLE 315 TURKEY MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 192
  • TABLE 316 TURKEY TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 317 TURKEY NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 318 TURKEY CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 319 TURKEY TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 320 TURKEY ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 193
  • TABLE 321 TURKEY CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 194
  • TABLE 322 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 323 TURKEY ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 324 TURKEY GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 325 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 194
  • TABLE 326 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 195
  • TABLE 327 TURKEY ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 195
  • TABLE 328 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 195
  • TABLE 329 TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 195
  • TABLE 330 REST OF EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 196

LIST OF FIGURES

  • FIGURE 1 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 36
  • FIGURE 2 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET : DATA TRIANGULATION 39
  • FIGURE 3 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DROC ANALYSIS 40
  • FIGURE 4 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 41
  • FIGURE 5 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 41
  • FIGURE 6 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MULTIVARIATE MODELLING 42
  • FIGURE 7 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 43
  • FIGURE 8 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DBMR MARKET POSITION GRID 44
  • FIGURE 9 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MARKET END USER COVERAGE GRID 45
  • FIGURE 10 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: VENDOR SHARE ANALYSIS 46
  • FIGURE 11 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 50
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 51
  • FIGURE 13 INCREASE IN THE PREVALENCE OF GLIOBLASTOMA MULTIFORME AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 52
  • FIGURE 14 PRIMARY (DE NOVO) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN 2022 & 2029 52
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET 62
  • FIGURE 16 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2021 72
  • FIGURE 17 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION) 73
  • FIGURE 18 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, CAGR (2022-2029) 73
  • FIGURE 19 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, LIFELINE CURVE 74
  • FIGURE 20 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2021 78
  • FIGURE 21 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION) 79
  • FIGURE 22 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, CAGR (2022-2029) 79
  • FIGURE 23 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, LIFELINE CURVE 80
  • FIGURE 24 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2021 90
  • FIGURE 25 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 91
  • FIGURE 26 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, CAGR (2022-2029) 91
  • FIGURE 27 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE 92
  • FIGURE 28 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2021 98
  • FIGURE 29 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 99
  • FIGURE 30 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029) 99
  • FIGURE 31 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE 100
  • FIGURE 32 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021 104
  • FIGURE 33 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 105
  • FIGURE 34 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 105
  • FIGURE 35 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 106
  • FIGURE 36 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2021 111
  • FIGURE 37 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION) 112
  • FIGURE 38 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, CAGR (2022-2029) 112
  • FIGURE 39 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, LIFELINE CURVE 113
  • FIGURE 40 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021 118
  • FIGURE 41 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 119
  • FIGURE 42 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 119
  • FIGURE 43 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 120
  • FIGURE 44 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021) 126
  • FIGURE 45 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021) 128
  • FIGURE 46 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 128
  • FIGURE 47 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 129
  • FIGURE 48 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022-2029) 129
  • FIGURE 49 EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%) 196
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!